MedTrace Logo

WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination

NCT00992563 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2014-07-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and effects of investigational drug AL-39324 for the treatment of wet AMD.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

AL-39324 ophthalmic suspension

DRUG

Ranibizumab 10 mg/mL

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Jennifer M. Kissner, Ph.D. · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-05-31
Completion
2011-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00992563 on ClinicalTrials.gov